Heptadecanoic acid
Based on 3 publication(s) in Google Scholar
Heptadecanoic acid is an odd-chain saturated fatty acid (OCS-FA) with oral activity. Heptadecanoic acid can inhibit cell proliferation and induce Apoptosis. Heptadecanoic acid has antitumor activity. Heptadecanoic acid is associated with a number of diseases, including coronary heart disease, pre-diabetes and type 2 diabetes, and multiple sclerosis.
For research use only. We do not sell to patients.
- Purity: 99.90%
- CAS No.: 506-12-7
- Formula: C17H34O2
- Molecular Weight:270.45
-
Storage:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Heptadecanoic acid
More
Biological Activity
|
Human Endogenous Metabolite |
Heptadecanoic acid (100 μM, 48 h) significantly inhibits the proliferation and migration of PC-9 and PC-9 /GR cells and promotes apoptosis by activating the PI3K/Akt signaling pathway[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PC‑9, PC‑9/GR
-
Concentration:100 μM
-
Incubation Time:48 h
-
Result:Significantly inhibited the proliferation of PC-9 and PC-9/GR cells in a dose-dependent.
-
Cell Line:PC‑9, PC‑9/GR
-
Concentration:100 μM
-
Incubation Time:48 h
-
Result:Inhibited the wound closure ratio of PC-9 and PC-9/GR cells.
Induced 16.62 and 29.63% apoptosis.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:NMS rats[2]
-
Dosage:5 mg/kg
-
Administration:p.o. (from day 10 to 14)
-
Result:Increased the cumulative amount of intracolonic and accelerated rat colonic motility.
Chemical Information
-
CAS No. 506-12-7
-
Appearance <59°C Solid,>61°C Liquid
-
Molecular Weight 270.45
-
Formula C17H34O2
-
Color White to off-white
-
SMILES
O=C(CCCCCCCCCCCCCCCC)O
-
Structure Classification
-
Initial Source
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (3)
-
Journal Impact Factor
-
Most Recent
Solvent & Solubility
DMSO : 100 mg/mL (369.75 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
H2O : < 0.1 mg/mL (insoluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 3 mg/mL (11.09 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 3 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (30.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (9.24 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (269 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Changzhi Xu, et al. Heptadecanoic acid inhibits cell proliferation in PC‑9 non‑small‑cell lung cancer cells with acquired gefitinib resistancey. Oncol Rep. 2019 Jun;41(6):3499-3507. [Content Brief]
[2]. Zhao L, et al. Saturated long-chain fatty acid-producing bacteria contribute to enhanced colonic motility in rats. Microbiome. 2018 Jun 14;6(1):107. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.6975 mL | 18.4877 mL | 36.9754 mL | 92.4385 mL |
| 5 mM | 0.7395 mL | 3.6975 mL | 7.3951 mL | 18.4877 mL | |
| 10 mM | 0.3698 mL | 1.8488 mL | 3.6975 mL | 9.2439 mL | |
| 15 mM | 0.2465 mL | 1.2325 mL | 2.4650 mL | 6.1626 mL | |
| 20 mM | 0.1849 mL | 0.9244 mL | 1.8488 mL | 4.6219 mL | |
| 25 mM | 0.1479 mL | 0.7395 mL | 1.4790 mL | 3.6975 mL | |
| 30 mM | 0.1233 mL | 0.6163 mL | 1.2325 mL | 3.0813 mL | |
| 40 mM | 0.0924 mL | 0.4622 mL | 0.9244 mL | 2.3110 mL | |
| 50 mM | 0.0740 mL | 0.3698 mL | 0.7395 mL | 1.8488 mL | |
| 60 mM | 0.0616 mL | 0.3081 mL | 0.6163 mL | 1.5406 mL | |
| 80 mM | 0.0462 mL | 0.2311 mL | 0.4622 mL | 1.1555 mL | |
| 100 mM | 0.0370 mL | 0.1849 mL | 0.3698 mL | 0.9244 mL |